Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

JW Therapeutics to Develop Two Additional 2seventy Cell Therapies in China

publication date: Sep 14, 2023

Shanghai JW Therapeutics will add two additional candidates for China to its T cell-based therapeutics collaboration with Boston’s 2seventy bio: a T-cell receptor molecule for solid tumors and a CAR T candidate for autoimmune diseases. The collaboration, announced last year, was set up to advance 2seventy products into clinical trials quickly. One of the two original products, a MAGE-A4 solid tumor program, is expected to start an investigator study later this year, which is faster than expected. JW was formed by Wuxi Apptec and Seattle’s Juno Therapeutics to bring cell therapies to China. More details....

Stock Symbols: (HK: 2126) (Nasdaq: TSVT)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
September 20-21 | Shanghai
September 25-26 | Digital
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China